Related Experiment Videos
Changes in platelet aggregation caused by glyburide in diabetic patients
Clinical Therapeutics
|January 1, 1984
Summary
Glyburide, an oral hypoglycemic, significantly reduced platelet aggregation in patients with maturity-onset diabetes. This finding suggests a potential antiplatelet effect of glyburide in diabetic individuals.
Area of Science:
- Pharmacology
- Endocrinology
- Hematology
Background:
- Platelet aggregation is a key factor in thrombotic events.
- Diabetes mellitus is associated with increased platelet activity.
- Glyburide is a common oral hypoglycemic agent.
Purpose of the Study:
- To investigate the effect of glyburide on platelet aggregation.
- To determine if glyburide has antiplatelet properties in diabetic patients.
Main Methods:
- 31 patients with maturity-onset diabetes were enrolled.
- Platelet aggregation was measured in platelet-rich plasma.
- Measurements were taken before and 1 hour after ingesting 5 mg of glyburide.
Main Results:
- Glyburide significantly decreased platelet aggregation.
- Changes in the amplitude and slope of the aggregation curve indicated reduced platelet activity.
Conclusions:
- Glyburide exhibits a significant inhibitory effect on platelet aggregation.
- This suggests a potential therapeutic benefit of glyburide beyond glycemic control in diabetic patients.